About: Outcomes of novel coronavirus disease 2019 (COVID‐19) infection in 107 patients with cancer from Wuhan, China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcomes of novel coronavirus disease 2019 (COVID‐19) infection in 107 patients with cancer from Wuhan, China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outcomes of novel coronavirus disease 2019 (COVID‐19) infection in 107 patients with cancer from Wuhan, China
Creator	Wang, Qun Zhang, Hongyan Wang, Xinghuan Xie, Conghua Yu, Yi Chen, Yuanyuan Shen, Xiaokun Wang, Linwei Wu, Qiuji Yan, Youqin Zhong, Yahua Chen, Gaili Chua, L Melvin, ;
Source	Medline; PMC
abstract	BACKGROUND: Patients with cancer have a higher risk of coronavirus disease 2019 (COVID‐19) than noncancer patients. The authors conducted a multicenter retrospective study to investigate the clinical manifestations and outcomes of patients with cancer who are diagnosed with COVID‐19. METHODS: The authors reviewed the medical records of hospitalized patients who were treated at 5 hospitals in Wuhan City, China, between January 5 and March 18, 2020. Clinical parameters relating to cancer history (type and treatment) and COVID‐19 were collected. The primary outcome was overall survival (OS). Secondary analyses were the association between clinical factors and severe COVID‐19 and OS. RESULTS: A total of 107 patients with cancer were diagnosed with COVID‐19, with a median age of 66 years (range, 37‐98 years). Lung (21 patients; 19.6%), gastrointestinal (20 patients; 18.7%), and genitourinary (20 patients; 18.7%) cancers were the most common cancer diagnoses. A total of 37 patients (34.6%) were receiving active anticancer treatment when diagnosed with COVID‐19, whereas 70 patients (65.4%) were on follow‐up. Overall, 52.3% of patients (56 patients) developed severe COVID‐19; this rate was found to be higher among patients receiving anticancer treatment than those on follow‐up (64.9% vs 45.7%), which corresponded to an inferior OS in the former subgroup of patients (hazard ratio, 3.365; 95% CI, 1.455‐7.782 [P = .005]). The detrimental effect of anticancer treatment on OS was found to be independent of exposure to systemic therapy (case fatality rate of 33.3% [systemic therapy] vs 43.8% [nonsystemic therapy]). CONCLUSIONS: The results of the current study demonstrated that >50.0% of infected patients with cancer are susceptible to severe COVID‐19. This risk is aggravated by simultaneous anticancer treatment and portends for a worse survival, despite treatment for COVID‐19.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1002/cncr.33042
bibo:pmid	32573776
has license	cc-by-nc
sha1sum (hex)	6bcdacc845c3811e97dc59c55222df525bdba52d
schema:url	https://doi.org/10.1002/cncr.33042
resource representing a document's title	Outcomes of novel coronavirus disease 2019 (COVID‐19) infection in 107 patients with cancer from Wuhan, China
has PubMed Central identifier	PMC7361610
has PubMed identifier	32573776
schema:publication	Cancer
resource representing a document's body	covid:6bcdacc845c3811e97dc59c55222df525bdba52d#body_text
is schema:about of	named entity 'detrimental' named entity 'relating' named entity 'cancer' named entity 'patients' named entity 'COVID-19' named entity 'cancer' named entity 'Patients' named entity 'Infection' named entity 'COVID-19' named entity 'WORSE' named entity '2856' named entity 'COMMON' named entity 'SECONDARY' covid:arg/6bcdacc845c3811e97dc59c55222df525bdba52d named entity 'total' named entity 'median age' named entity 'patients' named entity 'gastrointestinal' named entity 'receiving' named entity 'investigate' named entity 'patients' named entity 'RESULTS' named entity 'China' named entity 'COVID' named entity 'follow-up' named entity 'COVID' named entity 'COVID-19' named entity '95% CI' named entity 'Wuhan' named entity 'Infection' named entity 'liver' named entity 'OBservational studies' named entity 'quantitative RT-PCR' named entity 'immune checkpoint blockade' named entity 'ethics committee' named entity 'targeted therapy' named entity 'pulmonary parenchymal' named entity 'follow-up' named entity 'higher risk' named entity 'cancer treatments' named entity 'Wuhan' named entity 'mechanical ventilation' named entity 'STROBE' named entity 'comorbidities' named entity 'computed tomography scan' named entity '95% CI' named entity 'systemic therapy' named entity 'COVID' named entity 'dyspnea' named entity 'endocrine therapy' named entity 'higher risk' named entity 'virus entry' named entity 'baseline hematological' named entity 'stage IV' named entity 'comorbidities' named entity 'reverse transcriptase' named entity 'comorbidities' named entity 'constellation' named entity 'clinical presentation' named entity 'virus transmission' named entity 'COVID' named entity 'systemic therapy' named entity 'gastrointestinal' named entity 'lymphopenia' named entity 'COVID-19' named entity 'log-rank test' named entity 'intensive care unit' named entity 'clinical characteristics'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software